market access

Partner Content

$Banner for Media partners {460x250px}_3rd Genotoxic$

Partner Content

3rd Annual Impurities: Genotoxic and Beyond Summit

We are pleased to invite you to the 3rd Annual Impurities: Genotoxic and Beyond Summit scheduled for June 12th-13th, 2019.

Partner Content

$Banner for Media partners {460x250px}_5th Pre-Filled$

Partner Content

5th Annual Pre-Filled Syringes & Injectables Summit

Welcome to the 5th anniversary edition of the Pre-Filled Syringes & Injectables Summit on September 18-19, 2019, in Düsseldorf, Germany.

News

US drug cost body calls for SMA drug price cuts

A US drug cost-effectiveness group has said that Biogen should cut the price of its already-approved spinal muscular atrophy (SMA) drug, while the $4-$5 million Novartis is suggesting for a

News

NICE recommends interim funding for Lilly's breast cancer dr...

Final draft guidance from NICE has recommended interim NHS funding for Eli Lilly’s Verzenios (abemaciclib) with fulvestrant, giving certain breast cancer patients an option that can delay c

News

NICE backs funding for MSD's diabetes drug Steglatro

NICE has recommended that England’s NHS should routinely fund Merck, Sharpe, and Dohme’s type 2 diabetes drug Steglatro in a final decision, after the company undercut rivals from the same

News

Health secretary hints at 'constructive' talks over CF drugs

Health secretary Matt Hancock has offered hope to thousands of people in the UK who have been denied access to powerful cystic fibrosis drugs because of a row over pricing with manufacturer

3rd Annual Impurities: Genotoxic and Beyond Summit

5th Annual Pre-Filled Syringes & Injectables Summit

US drug cost body calls for SMA drug price cuts

NICE recommends interim funding for Lilly's breast cancer dr...

NICE backs funding for MSD's diabetes drug Steglatro

Health secretary hints at 'constructive' talks over CF drugs

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

market access

Editor's Picks